Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
Asset disposition
Acq. announced
Director departure
MEI Pharma, Inc. (MEIP) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
10/12/2023 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
10/10/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
10/10/2023 DEFC14A Form DEFC14A - Definitive proxy statement, contested solicitations:
10/03/2023 8-A12B Form 8-A12B - Registration of securities [Section 12(b)]:
10/03/2023 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "Certificate of Designation of Series A Junior Participating Preferred Stock of MEI Pharma, Inc",
"Rights Agreement, by and between MEI Pharma, Inc. and Computershare, Inc., as rights agent",
"MEI Pharma Adopts Limited-Duration Stockholder Rights Plan"
10/02/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/02/2023 PREC14A Form PREC14A - Preliminary proxy statements, contested solicitations:
09/29/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
09/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
09/28/2023 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
09/26/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
09/26/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
09/26/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights"
09/26/2023 10-K Annual Report for the period ended June 30, 2023
09/26/2023 DEFC14A Form DEFC14A - Definitive proxy statement, contested solicitations:
08/08/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
08/04/2023 PRRN14A Form PRRN14A - Non-management revised preliminary proxy soliciting materials, contested and otherwise:
07/27/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation and Release Agreement between the Company and Brian Drazba",
"Separation and Release Agreement between the Company and Brian Drazba"
07/24/2023 8-K Quarterly results
07/19/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
07/19/2023 425 Form 425 - Prospectuses and communications, business combinations:
07/19/2023 8-K Quarterly results
07/18/2023 425 Form 425 - Prospectuses and communications, business combinations:
07/18/2023 8-K Quarterly results
07/17/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
07/17/2023 SC 13D/A Anson Funds Management LP reports a 9.9% stake in MEI Pharma, Inc.
07/17/2023 425 Form 425 - Prospectuses and communications, business combinations:
07/17/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction SAN DIEGO, July 17, 2023 - MEI Pharma, Inc. today mailed the following letter to shareholders, encouraging them to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. in connection with the Company's special meeting on July 23, 2023, at 10:00 a.m. Eastern Time: Dear Fellow MEI Shareholders, We have extended the opportunity for shareholders to vote FOR our pending transaction with Infinity Pharmaceuticals, Inc. If you haven't voted yet, you can still do so today. Through this transaction, we are creating a combined company that is well capitalized and positioned to advance a diversified pipeline of three clinical-stage development programs. On a recent webcast, Dr. Ezra Cohen, a leading medical oncolo..."
07/17/2023 PREC14A Form PREC14A - Preliminary proxy statements, contested solicitations:
07/13/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/13/2023 425 Form 425 - Prospectuses and communications, business combinations:
07/13/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"MEI Pharma Postpones Special Meeting of Shareholders"
07/10/2023 PX14A6G Form PX14A6G - Notice of exempt solicitation submitted by non-management:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy